Cat allergy immunotherapy - Circassia

Drug Profile

Cat allergy immunotherapy - Circassia

Alternative Names: Cat allergen vaccine - Circassia; Cat peptide allergen desensitisation; Cat Synthetic Peptide Immuno-Regulatory Epitopes; Cat-PAD; ToleroMune; ToleroMune Cat

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Circassia
  • Class Allergens; Antiallergics; Cat allergy immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 18 Apr 2017 Efficacy data from the phase III trial in Allergic rhinoconjunctivitis released by Circassia Pharmaceuticals
  • 03 Mar 2017 Adverse events data from a phase II trial in Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 30 Jun 2016 Circassia completes the phase III CATALYST trial for Allergic rhinoconjunctivitis in USA, Canada, Belgium, Czech Republic, Germany, Hungary, Poland, Slovakia and Russia (NCT01620762)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top